Drug Profile
Research programme: oncolytic vaccinia viruses - SillaJen Biotherapeutics
Alternative Names: JX-900; JX-963; JX-970; SJ 815; SJ 963Latest Information Update: 24 Jul 2023
Price :
$50
*
At a glance
- Originator Jennerex Biotherapeutics
- Developer Jennerex; SillaJen Biotherapeutics
- Class Cancer vaccines; Oncolytic viruses
- Mechanism of Action Epidermal growth factor receptor antagonists; Immunostimulants; Ras signal transduction pathway inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Solid tumours
- No development reported Cancer
Most Recent Events
- 24 Jul 2023 Preclinical development is ongoing in USA (SillaJen Biotherapeutics pipeline, July 2023)
- 28 Nov 2022 No recent reports of development identified for preclinical development in Solid-tumours in USA (Parenteral)
- 28 Feb 2021 No recent reports of development identified for preclinical development in Cancer in USA (Parenteral)